Hepatitis B virus (HBV) antigen‐pulsed monocyte‐derived dendritic cells from HBV‐associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro

Summary To investigate whether hepatitis B virus (HBV) antigen‐pulsed monocyte‐derived dendritic cells (MoDC) could mount a T cell response in hepatocellular carcinoma (HCC) patients associated with chronic HBV infection, peripheral blood mononuclear cells (PBMCs) from 36 HBV‐associated HCC patients were induced into MoDC and pulsed with hepatitis B core antigen (HBcAg) and hepatitis B surface antigen (HBsAg), alone and in combination. Co‐stimulatory molecules CD80, CD86 and CD40, as well as human leucocyte antigens D‐related (HLA‐DR) were found to express at the highest level on MoDC pulsed with HBcAg or HBsAg + HBcAg, at a median level on MoDC pulsed with HBcAg or HBsAg alone, and at the lowest level on non‐antigen‐pulsed MoDC. Interleukin (IL)‐10 and IL‐12 cytokines were released by antigen‐pulsed MoDC at increased levels in the order: no‐antigen <  HBsAg < HBcAg < HBcAg + HBsAg. MoDC pulsed with HBcAg or HBsAg + HBcAg also had the strongest ability to stimulate autologous T cell proliferation and intracellular interferon (IFN)‐γ production. HBcAg‐ or HBsAg + HBcAg‐pulsed MoDC could also induce HBV core peptide‐specific CD8 + T cell proliferation determined by tetramer staining. In addition, the antigen‐pulsed MoDC were found to have a stronger capacity to produce IL‐12 and induce T cell response in vitro for patients with higher alanine transaminase (ALT) levels than those with lower ALT levels, indicating that antigen pulse could substantially reverse the impaired function of MoDC in primary HCC patients with active chronic hepatitis B. In conclusion, HBV antigen‐pulsed MoDC from HCC patients with chronic hepatitis B could induce HBV‐specific T cell response in vitro .